Subcutaneous immunoglobulin - the future of CIDP treatment?

被引：4
|
作者：
Wakerley, Benjamin R. [1 ,2 ]
Yuki, Nobuhiro [3 ]
机构：
[1] Gloucestershire Royal Hosp, Dept Neurol, Great Western Rd, Gloucester GL1 3NN, England
[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Headley Way, Oxford OX3 9DU, England
[3] Eda Mem Hosp, Dept Med, Aoba Ku, Azamino Minami 1-1-1, Yokohama, Kanagawa 2250012, Japan
来源：
NATURE REVIEWS NEUROLOGY | 2018年 / 14卷 / 03期
基金：
英国医学研究理事会;
关键词：
GUILLAIN-BARRE-SYNDROME;
D O I：
10.1038/nrneurol.2017.179
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Results from the PATH study indicate that subcutaneous immunoglobulin is efficacious and well tolerated for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). This finding represents an important step in the management of patients with immunoglobulin-responsive CIDP, with considerable implications for the cost of treatment and, most importantly, for these patients' quality of life.
引用
收藏
页码：130 / 132
页数：2
相关论文
共 50 条
  • [1] Subcutaneous immunoglobulin — the future of CIDP treatment?
    Benjamin R. Wakerley
    Nobuhiro Yuki
    Nature Reviews Neurology, 2018, 14 : 130 - 131
  • [2] , Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs
    Markvardsen, Lars H.
    Harbo, Thomas
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 378 : 19 - 25
  • [3] Practical application of subcutaneous immunoglobulin for maintenance treatment in CIDP: The PATH study
    Dimachkie, Mazen
    van Schaik, Ivo
    Bril, Vera
    van Geloven, Nan
    Hartung, Hans-Peter
    Lewis, Richard
    Sobue, Gen
    Lawo, John-Philip
    Mielke, Orell
    Durn, Billie
    Cornblath, David
    Merkies, Ingemar
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 357 - 358
  • [4] SUBCUTANEOUS IMMUNOGLOBULIN IN CIDP: A TWO-YEAR EXPERIENCE
    Topa, A.
    Spina, E.
    Iodice, R.
    Tozza, S.
    Ruggiero, L.
    Dubbioso, R.
    Esposito, M.
    Santoro, L.
    Manganelli, F.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2017, 22 : S41 - S41
  • [5] SUBCUTANEOUS IMMUNOGLOBULIN IN CIDP: A TWO-YEAR EXPERIENCE
    Topa, A.
    Spina, E.
    Iodice, R.
    Tozza, S.
    Ruggiero, L.
    Dubbioso, R.
    Esposito, M.
    Santoro, L.
    Manganelli, F.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2017, 22 (03) : 397 - 397
  • [6] Subcutaneous is better tolerate than intravenous immunoglobulin treatment: the experience with two CIDP patients
    Pasini, E.
    Liguori, R.
    Avoni, P.
    Donadio, V.
    JOURNAL OF NEUROLOGY, 2014, 261 : S357 - S357
  • [7] SUBCUTANEOUS IMMUNOGLOBULIN IN CIDP: A 5 YEARS FOLLOW UP
    Mazzeo, A.
    Gentile, L.
    Barcellona, C.
    Vita, G.
    Toscano, A.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 : S27 - S27
  • [8] Subcutaneous is better tolerated than intravenous immunoglobulin treatment: the experience with two CIDP patients
    Pasini, E.
    Liguori, R.
    Avoni, P.
    Donadio, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 544 - 544
  • [9] Nationwide randomized trial of two standardized regimen for tapering off subcutaneous immunoglobulin treatment in CIDP
    Markvardsen, Lars
    Sindrup, Soren
    Holbech, Jakob
    Christiansen, Ingelise
    Andersen, Henning
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 499 - 500
  • [10] Subcutaneous "bolus" immunoglobulin dose in CIDP: A proof-of concept study
    Cocito, Dario
    Peci, Erdita
    Romagnolo, Alberto
    Rigaldo, Simona
    Rosso, Michela
    Lopiano, Leonardo
    Merola, Aristide
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 380 : 54 - 57
12345